Literature DB >> 2536779

Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination.

M G Thomas1, K Redhead, H P Lambert.   

Abstract

We used an immunoblotting technique to compare the serum antibody responses to pertussis toxin (PT), filamentous hemagglutinin (FHA), a 69-kilodalton (kDa) adenylate cyclase-associated protein (69 KD protein), and Bordetella pertussis outer membrane proteins (OMPs) following either B. pertussis infection or immunization with whole-cell pertussis vaccine. Infection and vaccination induced nearly equally intense antibody responses to PT and to FHA, but vaccination induced stronger antibody responses to the 69 KD protein and to many OMPs. The importance of serum antibody responses to the 69 KD protein and to B. pertussis OMPs other than PT and FHA in conferring immunity to pertussis after vaccination is unknown. Serum antibody responses to PT following either infection or vaccination were almost exclusively to the 28-kDa enzymatic subunit (S1) and only rarely and weakly to the lesser molecular weight binding subunits (S2-S5).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536779     DOI: 10.1093/infdis/159.2.211

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.

Authors:  S Esposito; T Agliardi; A Giammanco; G Faldella; A Cascio; S Bosis; O Friscia; M Clerici; N Principi
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis.

Authors:  J W Petersen; P H Ibsen; K Hasløv; I Heron
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

3.  Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.

Authors:  J L Arciniega; R D Shahin; W N Burnette; T D Bartley; D W Whiteley; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

4.  Effect of hydromechanical stress on cellular antigens of Bordetella pertussis.

Authors:  M E Rodriguez; D F Hozbor; O M Yantorno
Journal:  J Ind Microbiol       Date:  1996-07

Review 5.  Laboratory diagnosis of pertussis: state of the art in 1997.

Authors:  F M Müller; J E Hoppe; C H Wirsing von König
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

6.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  Identification of B-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  P H Ibsen; A Holm; J W Petersen; C E Olsen; I Heron
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

8.  Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV).

Authors:  Yong-Zhang Zhu; Cheng-Song Cai; Wei Zhang; Hong-Xiong Guo; Jin-Ping Zhang; Ya-Yong Ji; Guang-Yuan Ma; Jia-Lin Wu; Qing-Tian Li; Cheng-Ping Lu; Xiao-Kui Guo
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

9.  Identification of human T-cell epitopes on the S4 subunit of pertussis toxin.

Authors:  J W Petersen; A Holm; P H Ibsen; K Hasløv; C Capiau; I Heron
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

10.  Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.

Authors:  G Kanra; M Ceyhan; D Vandevoorde; H Bogaerts
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.